Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients
with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer,
melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that
have failed to respond to standard therapy, progressed despite standard therapy, for which
standard therapy does not offer the potential for increased survival.